Clinical Therapeutics

Clinical Therapeutics was a biotechnology company focused on the development of novel small molecule therapies for oncology and neurodevelopmental disorders. The company's lead research centered on tyrosine hydroxylase inhibitors, specifically the development of L1-79 (a racemic formulation of alpha-methylparatyrosine). Its technology was designed to modulate catecholaminergic pathways to treat the core symptoms of autism spectrum disorder and to disrupt metabolic pathways in various cancer types. The company's assets and programs were eventually integrated into or advanced by successor entities such as Tyme Technologies and Yamo Pharmaceuticals.